Protheragen Highlights Comprehensive Medical Device Testing and Analytical Services to Support Global Regulatory Compliance

New York, United States, October 20, 2026 /MarketersMEDIA/ -- Protheragen, an ISO9001-certified preclinical contract research and analytical service provider, is emphasizing its integrated suite of services designed to help medical device manufacturers navigate rigorous regulatory pathways and bring safe, effective products to market. Its medical device analytical services span the full development lifecycle, addressing critical areas such as safety, biocompatibility, and performance validation.

The medical device industry faces increasing scrutiny from regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Protheragen supports global medical device firms by delivering end‑to‑end solutions throughout the full product development lifecycle, combining hands‑on testing expertise with deep regulatory knowledge.

Medical device safety testing is essential for reducing risk and preventing adverse patient events. Protheragen’s safety testing service includes bacterial endotoxin testing (BET) using state-of-the-art horseshoe crab lysates (LAL)) assays to quantify pyrogens, as well as sterility testing and bioburden testing to assess microbial contamination. These safety assessments are further complemented by antimicrobial efficacy testing, packaging integrity evaluations, and regulatory support to ensure devices meet stringent quality control requirements before approval.

In addition, Protheragen conducts thorough biocompatibility studies in accordance with ISO 10993 standards to evaluate how device materials interact with living tissues and biological systems. Its biological risk assessment covers a wide range of endpoints, including cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, implantation effects, and hematological compatibility. By identifying potential local or systemic reactions—such as inflammation, toxicity, or allergic responses—these studies provide critical data for regulatory submissions and help confirm patient safety.

Beyond safety and biological evaluation, Protheragen also delivers rigorous validation and verification studies to confirm that medical devices consistently perform as intended and meet all design and manufacturing specifications. This service includes requirement analysis, usability and human factors testing, risk assessment, performance testing, and comprehensive documentation. Separately, process validation and verification services help ensure manufacturing consistency through protocol development, statistical analysis, critical process parameter control, and ongoing monitoring strategies. Additional support in risk management, quality management system (QMS) implementation, and regulatory compliance further strengthens Protheragen’s end-to-end medical device services.

Protheragen emphasizes that its integrated approach—combining medical device safety testing, biocompatibility studies, and validation & verification services—is designed to help clients mitigate risks, achieve regulatory compliance, and accelerate the delivery of safe medical devices to the global market.

About Protheragen

Protheragen is an ISO9001-certified supplier of preclinical contract research services and analytical services. Located in New York, the company provides comprehensive testing support to the pharmaceutical and medical device industries, with a focus on regulatory adherence, scientific rigor, and patient safety.

Contact Info:
Name: Hannah Green
Email: Send Email
Organization: Protheragen
Website: https://labs.protheragen.ai/

Release ID: 89206735

In the event of encountering any errors, concerns, or inconsistencies within the content shared in this press release, we kindly request that you immediately contact us at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will be readily accessible to address your feedback within 8 hours and take appropriate measures to rectify any identified issues or facilitate press release takedowns. Ensuring accuracy and reliability are central to our commitment.